Testing zamtocabtagene autoleucel in people with B cell lymphoma that came back or did not respond
Official title: DALY II USA/ MB-CART2019.1 for DLBCL
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study is testing a treatment called zamtocabtagene autoleucel in people whose B cell lymphoma came back or did not get better with earlier treatment.
Read our full plain-language summary
What the trial team says
DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory B cell lymphoma (BCL). Cohorts include subjects with diffuse large B-cell lymphoma (DLBCL) after receiving at least 2 lines of therapy, primary or secondary central nervous system (CNS) lymphoma (PCNSL) and (SCNSL) after receiving at least one line of therapy, mantle cell lymphoma (MCL) and Richter's transformation (RT) after receiving at least one line of therapy, and DLBCL transplant-ineligible after receiving at least one line of therapy.
Key facts
- Registry number
- NCT04792489
- Stage of testing
- Phase 2
- Conditions studied
- Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma (HGBCL), Primary Mediastinal B-cell Lymphoma (PMBCL), Transformed Lymphoma, Central Nervous System Lymphoma, Mantle Cell Lymphoma (MCL), Richter Transformation, Transplant-ineligible 2nd Line DLBCL
Where it is running
This trial lists 32 sites.
-
Alabama
- University of Alabama at Birmingham (Birmingham)
-
Alberta
- University of Alberta Cross Cancer Institute (Edmonton)
-
Arizona
- Banner MD Anderson Cancer Center (Gilbert)
- Mayo Clinic (Phoenix)
-
California
- UC San Diego Health (La Jolla)
- Stanford University (Stanford)
-
Colorado
- Colorado Blood Cancer Institute (Denver)
-
Connecticut
- Yale University (New Haven)
-
Florida
- Baptist Health Miami Cancer Institute (Miami)
-
Georgia
- Winship Cancer Institute of Emory University (Atlanta)
- Georgia Cancer Center at Augusta University (Augusta)
-
Illinois
- Robert H Lurie Cancer Center (Chicago)
-
Kansas
- University of Kansas Cancer Center (Westwood)
-
Maryland
- University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (Baltimore)
-
Massachusetts
- Dana Farber Cancer Institute (Boston)
-
Michigan
- University of Michigan (Ann Arbor)
-
Minnesota
- Mayo Clinic (Rochester)
-
Missouri
- Washington University, St. Louis (St Louis)
-
Nebraska
- University of Nebraska Medical Center (Omaha)
-
New York
- Memorial Sloan Kettering Cancer Center (New York)
-
North Carolina
- Duke University Medical Center - Division of Hematologic Malignancies (Durham)
-
Ohio
- The Ohio State University Wexner Medical Center James Cancer (Columbus)
-
Ontario
- Princess Margaret Cancer Centre (Toronto)
-
Oregon
- Oregon Health and Science University Knight Cancer Institute (Portland)
-
Pennsylvania
- Allegheny Health Network Cancer Institute (Pittsburgh)
- University of Pittsburgh - Hillman Cancer Center (Pittsburgh)
-
Tennessee
- SCRI Oncology Partners (Nashville)
-
Texas
- UT Southwestern Medical Center (Dallas)
- The University of Texas MD Anderson Cancer Center (Houston)
- Texas Transplant Institute (San Antonio)
-
Washington
- Fred Hutchinson Cancer Center (Seattle)
-
Wisconsin
- Froedtert Hospital and the Medical College of Wisconsin (Milwaukee)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.